The Evolution of Competitive Landscape Behind the Best Pharmaceutical Agent Tirzepatide in 2023
Recently, the Galien Foundation in the United States announced the winners of the Prix Galien USA Awards, often acknowledged as the "Nobel Prize of the pharmaceutical industry.” This prestigious award honors distinguished scientific innovation that significantly contributes to the improvement of human health and is considered one of the highest accolades in the pharmaceutical and biomedicine industries. It is worth noting that among the winners this year, Ozempic from Novo Nordisk and Mounjaro from Eli Lily and Company were awarded this outstanding recognition for their breakthrough therapies!
Mounjaro (tirzepatide) is a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It was approved by the US FDA in May 2022 for use in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. According to the press release of Eli Lily, Mounjaro represents the first new type of diabetes medication in nearly a decade.
Semaglutide, marketed as Ozempic, was approved by the US FDA in 2017 for the control of blood glucose in patients with type 2 diabetes. Semaglutide is a GLP-1 receptor agonist that stimulates the production of insulin and inhibits the secretion of glucagon, thereby reducing appetite and food intake. In June 2021, semaglutide injection (once weekly, 2.4 mg), marketed as Wegovy, was approved by the FDA for the first time for the treatment of obesity. This marked the first new weight loss medication approved by the FDA since 2014.
A Panoramic View of Tirzepatide’s Top 10 Patent Assignees
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Tirzepatide patent are as follows: Eli Lilly with 101 applications, Sun Pharmaceutical with 14 applications, and Applied Molecular Transport with 8 applications. For more applicants, please refer to the image below.
Source, Patsnap Bio
Evolution of the Layout of Top 10 Patent Assignees over the years, the Competitive landscape over time
Exploring the changes occurring within the application structure amongst tirzepatide's top 10 patent assignees over time delivers insights into the competitive landscape's evolution.
Source, Patsnap Bio
So, How Can You Access Comprehensive Data on Tirzepatide Sequence Patents at No Cost?
Firstly, establish a free account with Patsnap Bio Sequence Database. Proceed to the homepage's "standard search," and enter the tirzepatide sequence or directly input the drug name, tirzepatide, in the "Drug/Gene index.” This single action will unravel extensive details of tirzepatide's sequence, patent, literature, data from diversified sources, and a visually competitive landscape of patents.
The left panel's search result details page is equipped with an exhaustive range of filters, enabling you to pinpoint specific data accurately, thereby boosting your search experience and overall efficiency. Clicking on each data point will unfold a rich and detailed data set and a host of advantageous and practical tools to support your research process.
It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.
Free registration is available for the Bio biological sequence database: https://bio-patsnap-com.libproxy1.nus.edu.sg. Act now to expedite your sequence search tasks.
